Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon(University of Manchester), Matthew D. Hellmann(Memorial Sloan Kettering Cancer Center), Darwin Ye(Cancer Research Institute), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Ross Stewart(AstraZeneca (United Kingdom)), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Marta Łuksza(Memorial Sloan Kettering Cancer Center), Jingya Qiu(Cancer Research Institute), Kyung Jin Yoo(Lemuel Shattuck Hospital), Caroline G. McCarthy(Memorial Sloan Kettering Cancer Center), George Fromm(Lemuel Shattuck Hospital), Divij Mathew(Parker Institute for Cancer Immunotherapy), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Jia Luo(Army Medical University), J. Carl Barrett(AstraZeneca (United States)), Mohamed Reda Keddar(AstraZeneca (United Kingdom)), Pedro Beltrão(SIB Swiss Institute of Bioinformatics), Mohsen Abu-Akeel(Swim Across America), Nicholas McGranahan(London Cancer), Jennifer L. Sauter(Memorial Sloan Kettering Cancer Center), Benjamin D. Greenbaum(Tisch Hospital), Andrew Chow(Icahn School of Medicine at Mount Sinai), Cailian Liu(Memorial Sloan Kettering Cancer Center), Ikbel Achour(AstraZeneca (United Kingdom)), Martin L. Miller(Cancer Research UK), Xiang H.-F. Zhang(Texas Medical Center), Jayon Lihm(Memorial Sloan Kettering Cancer Center), Umesh Bhanot(Memorial Sloan Kettering Cancer Center), Chad Vanderbilt(Memorial Sloan Kettering Cancer Center), Andy J. Minn(Cancer Research Institute), Taylor H. Schreiber(Lemuel Shattuck Hospital), Jayalaksmi Miriyala(Lemuel Shattuck Hospital), Taha Merghoub(Weill Cornell Medicine)
Cited by 177
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k